Trials / Unknown
UnknownNCT04550637
A Multi-center Study of Apixaban(APPROACH)
A Multi-center Observative Study of Apixaban After Left Atrial Appendage Occlusion in Patients With Non-valvular Atrial Fibrillation
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The aim of the study is to enroll approximately 200 cases from 10 research centers nationwide, completed left atrial appendage occlusion (LAAO) successfully, and give apixaban (5 mg bid) postoperatively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oral apixaban | apixaban (5 mg bid) is given until 12 weeks after surgery |
Timeline
- Start date
- 2022-07-04
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
- First posted
- 2020-09-16
- Last updated
- 2022-10-18
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04550637. Inclusion in this directory is not an endorsement.